HER2-targeted therapies effectively control systemic disease, but their efficacy against brain metastases is hindered by their low penetration of the blood-brain and blood-tumor barriers (BBB and BTB). We investigate brain uptake and antitumor efficacy of transferrin receptor (TfR)-targeted, therapeutic nanoparticles designed to transcytose the BBB/BTB in three murine models.
| INTRODUCTION
Human epidermal growth factor receptor 2 (HER2) protein overexpression is observed in about 25% of human breast cancers. It confers a more aggressive phenotype and, historically, has been associated with poor patient prognosis.
1 HER2-targeted therapies, such as the anti-HER2 antibody (Ab) trastuzumab, have been shown to improve outcomes in patients with HER2-positive, metastatic disease. However, with improved control of systemic disease and prolonged survival, the incidence of brain metastases is increasing in these patients. 2, 3 Currently, as many as half of patients with HER2-positive, metastatic breast cancer develop brain metastases over time. 4 Treatment of these brain tumors is a growing clinical challenge, in large part due to the poor penetration of HER2-targeted agents through the blood-brain barrier (BBB). 4, 5 There is considerable debate in the literature regarding the extent to which the BBB remains intact with brain metastases (in the form of the blood-tumor barrier [BTB] ). In general, chemotherapy has not proven to be effective in the clinic. 6 However, there have been a few examples of specific combinations showing clinical activity. 7 Recent studies in experimental brain metastasis models reveal that, although the majority of metastases have some increased vascular permeability, their uptake of chemotherapeutics is limited. 8 Furthermore, significant heterogeneity in therapeutic uptake is observed in brain metastases resected from patients, both among patients and within individual lesions. 9 Additionally, an investigation of breast cancer subtypes showed that there is no significant disruption of the barrier by brain metastases resected from patients with HER2-positive breast cancer. 10 Thus, while brain metastases may have some increased permeability, approaches to overcome limited drug delivery to the brain will be important to improve clinical outcomes, particularly for HER2-positive, metastatic disease.
Of the many strategies to increase brain penetration of systemic therapeutics, perhaps one of the most promising is the use of receptor-mediated transcytosis (RMT). 11, 12 Transferrin receptor (TfR) has been actively explored for RMT across the BBB, due to its high expression on BBB endothelium. 13 In particular, anti-TfR Abs has garnered the most interest because of their ability to bind TfR with high affinity without interfering with endogenous transferrin (Tf ). 14, 15 Results from initial studies suggested that reducing the affinity of anti-TfR Abs to TfR maximizes their uptake into the brain parenchyma. 16 Further investigation revealed that affinity influences intracellular trafficking; high-affinity anti-TfR Abs are trafficked to the lysosome, while lower-affinity variants are more capable of transcytosis. 17 Recently, it has been shown that bivalent Ab:TfR binding leads to lysosomal sorting, whereas monovalent binding facilitates transcytosis. 18 In addition to affinity and valency, in vitro results suggest that pH-sensitivity of TfR binding also affects trafficking of anti-TfR Abs;
an Ab with reduced affinity at endosomal pH 5.5 showed a greater ability to transcytose than pH-independent Abs of comparable affinities at extracellular pH 7.4. 19 However, despite a more detailed understanding of the properties that promote transcytosis, several challenges exist in translating anti-TfR Abs into the clinic, including the need to: (a) dose very high quantities, 15 (b) mitigate effectorfunction driven safety concerns, 20 and (c) develop species-specific Abs. 21 Motivated by the results from anti-TfR Ab trafficking at the BBB, we began to investigate how fundamental properties of TfR-targeted nanoparticles affect their transcytosis capacity. 22 Targeted nanoparticles were chosen for their ability to deliver large quantities and a variety of drugs to specific tissues at well-controlled release rates. 23 In analogy to the results obtained with anti-TfR Abs, Tf-coated gold nanoparticles (AuNPs) with reduced avidity to TfR demonstrated the greatest ability to cross the BBB. 22 Despite showing promise, questions regarding the need for very high systemic dosing to achieve sufficient brain accumulation led to alternative nanoparticle designs.
Recently, an acid-cleavable targeting strategy was incorporated into the nanoparticle design to increase the ability of high-avidity nanoparticles to enter the brain. 24 With this design, nanoparticles can bind TfR with high avidity on the blood side of the BBB to enable practical, systemic dosing, but shed the targeting ligands upon acidification during transcytosis, 25 allowing free diffusion into the parenchyma ( Figure 1a) . Incorporation of an acid-cleavable linkage between
Tf and the nanoparticle core increased brain uptake of high-avidity Tfcoated AuNPs nearly threefold. 24 In contrast, no improvement was observed with high-affinity anti-TfR-coated AuNPs with the cleavable linker, consistent with their trafficking to the lysosome. These results suggest that intracellular trafficking may also be affected by the particular targeting ligand.
Here, we determine whether nanoparticles can be prepared to deliver therapeutic quantities of drug across the BBB. We focused on HER2-positive breast cancer brain metastasis because of the inadequate drug concentrations achieved in these tumors in the clinical setting. Although a number of preclinical models for this disease have emerged in the literature, the effect of the method used to establish metastatic brain tumors on therapeutic brain penetration has not been examined. To address these questions, we adapted a targeted nanoparticle delivery system for camptothecin (CPT) previously developed in our lab for its use at the BBB. 26, 27 Tf was attached to nanoparticles consisting of a mucic acid polymer (MAP) conjugate of CPT (MAP-CPT) through a pH-dependent, boronic acid-diol complexation to form TfR-targeted MAP-CPT nanoparticles (Figure 1b) . We investigated antitumor efficacy and brain uptake of these nanoparticles in two types of models from the literature, as well as a new, third model we developed that more closely mimics the metastasis process in patients. We found that this targeted nanoparticle delivery system can be used to deliver CPT to HER2-positive breast cancer brain metastases. Importantly, we also observed significant differences in efficacy as well as brain penetration of both TfR-targeted and nontargeted therapeutics between the models, showing that the method of establishing brain metastases can affect brain uptake of therapeutic agents. 
| Synthesis of CO 2 H-PEG-nitroPBA and OMe-PEG-nitroPBA
3-carboxy-5-nitrophenyl boronic acid (nitroPBA) was reacted with oxalyl chloride to prepare 3-acyl chloride-5-nitrophenyl boronic acid.
The acyl chloride was reacted with either CO 2 H-PEG-NH 2 or OMe-PEG-NH 2 to prepare CO 2 H-PEG-nitroPBA and OMe-PEG-nitroPBA, respectively.
| Synthesis of Tf-PEG-nitroPBA
Tf was coupled to CO 2 H-PEG-nitroPBA using EDC/NHS chemistry to prepare Tf-PEG-nitroPBA. Protein conjugation was verified by MALDI-TOF, using a sinapinic acid matrix.
| Preparation of nanoparticles
Either OMe-PEG-nitroPBA or Tf-PEG-nitroPBA conjugates were added at 20x molar excess to MAP-CPT nanoparticles to form nontargeted and TfR-targeted nanoparticles in PBS, pH 7.4 (20 OMe or Tf per particle). 2.7 | Antitumor efficacy in IC, ICD, and IV brain metastasis models 3 | RESULTS AND DISCUSSION
| Nanoparticle characterization

| Synthesis and characterization of TfR-targeted and nontargeted MAP-CPT nanoparticles
MAP-CPT nanoparticles were chosen for this study because they retained the optimal design parameters identified in our previous
AuNP formulations, including a sub-100-nm diameter and nearneutral zeta potential. 22 It has also been shown that these characteristics facilitate the diffusion of nanoparticles through brain tissue. 28 The ketal linker previously investigated as the acid-cleavable moiety between the Tf and the nanoparticle did not provide optimal cleavage kinetics to remove all surface Tf during transcytosis. 24 The MAP delivery system allows for assembly of TfR-targeted nanoparticles using an improved acid-cleavable chemistry (Figure 1b) , as discussed below.
Furthermore, MAP-CPT nanoparticles targeted with an antibody have already been used to effectively treat breast cancer xenografts in mice. 27 MAP-CPT conjugate was synthesized in a similar manner to that previously described (Supporting Information Figure S1 ). 26 Properties of the material used in this study are provided in Supporting Information Table S1 . MAP-CPT conjugate was dialyzed against water to promote formation of nanoparticles with hydrophobic CPT molecules preferentially clustered in the core and vicinal diols on the surface (Figure 1b) .
The boronic acid derivative, 3-carboxy-5-nitrophenyl boronic acid (nitroPBA), was added to 5-kDa polyethylene glycol (PEG), followed by conjugation of the polymer to human holo-Tf (Supporting Information Figure S2A ). A non-targeted analog was prepared using methoxyterminated 5-kDa PEG (Supporting Information Figure S2B ). NitroPBA was chosen because it forms a boronic acid ester with the MAP-CPT diols and has a pKa of 6.8. Table S3 ). Importantly, brain tumors developed in a majority of the mice (>90%) before they succumbed to visceral tumor burden, with a distribution similar to that observed in patients (Supporting Information Figure S5 Table S5 ). However, treatment with nontargeted MAP-CPT nanoparticles or CPT also led to substantial tumor growth inhibition (3.5-or 2.6-fold reduction in mean final tumor volume, respectively), supporting the hypothesis that artificial transport pathways may be introduced following IC tumor establishment. The blood Gluc activity for each treatment group correlated well with tumor volume, as measured by MRI (Supporting Information Figure S9 ). Individual antitumor data are provided in Supporting Information Figure S10 .
In contrast to results from the IC model, only treatment with TfRtargeted MAP-CPT nanoparticles resulted in substantial tumor growth delay compared to saline when tumors were established by ICD injection (2.6-fold decrease in mean tumor volume; Figure 3b and Supporting Information Table S6 ). Interestingly, we observed a modest response with CPT treatment, but not with nontargeted MAP-CPT nanoparticles (although this difference was not significant).
Similar to the ICD model, with IV-established brain tumors, TfRtargeted MAP-CPT nanoparticles markedly slowed tumor growth compared to saline (2.5-fold decrease in mean tumor volume; Figure 3c and Supporting Information Table S7 ). Notably, no tumor growth inhibition was observed with CPT or nontargeted MAP-CPT nanoparticles compared to saline in this model, more closely replicating the clinical situation.
| Brain uptake of therapeutics differs in tumor, but not healthy tissue between models
To ascertain whether differences in brain penetration of the therapeutics might explain the discordance in efficacy between brain metastasis models, we systemically administered an additional dose of each treatment at the end of the efficacy study. After 24 hr, mice were anesthetized and perfused with PBS to clear any remaining nanoparticles or free drug from the bloodstream. Drug uptake into tumor and healthy brain tissue was quantified by HPLC as previously described. Tables S5-S7 parental cells had comparable sensitivities to CPT in vitro (Supporting Information Figure S11 ), ruling out permanent, model-specific drug sensitivity as the origin for anti-tumor differences. Although there is evidence that brain-specific drug resistance mechanisms may also be important, 7 these data strongly implicate BBB/BTB permeability to the therapeutic agents as a key mediator of the differential treatment response between the models in this study.
Importantly cells (relative to other breast cancer cell lines). 26 Thus, it is encouraging to observe tumor growth delay when delivering CPT via targeted nanoparticles to the BT474-Gluc brain metastases. It is expected that TfRtargeted nanoparticles delivering therapeutic agents with greater potency will reveal even more significant tumor size reductions.
Further, it is important to note that TfR-targeted nanoparticles accumulated in significant amounts in healthy brain tissue when compared to free drug and nontargeted nanoparticles in all three models.
This observed whole-brain penetration has implications for the selection of therapeutics that should be incorporated into this delivery system and of target diseases. In the case of brain cancers, the ability to penetrate not only tumor tissue, but also healthy tissue could be advantageous in accessing micrometastases or fingers of glioma tumors that are frequently the reason for treatment failure. At the same time, the broad nanoparticle accumulation in the brain will require careful thought as to which drugs are used in this application, due to potential toxicity issues. For other brain diseases where whole-brain therapeutic exposure is highly desired, such as neurodegenerative diseases, this targeted nanoparticle system may offer a compelling approach to delivering therapeutics across an intact BBB.
Here, we show that the method used to establish breast cancer brain metastases can affect efficacy and brain uptake of therapeutic agents. We observed a significant antitumor response as well as brain Tables S8 and S9 tumor accumulation of a non-BBB-penetrant small molecule and a non- 
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